Eight-hundred and thirty-six patients were randomised to therapy at 25 sites in the United States and received at least one dose of loratadine (n = 357), fexofenadine (n = 360) or placebo (n = 119).

Objective: To compare loratadine with fexofenadine and placebo in relieving symptoms of seasonal allergic rhinitis (SAR). Design: A randomised, double-blind, double-dummy, placebo-controlled ...